Literature DB >> 33390292

Adjuvant effect of type I interferon induced by many but not all commercial influenza vaccines.

Sofi Damjanovska1, Carson Smith2, Ismail Sayin1, Christopher J Burant3, Stefan Gravenstein4, David H Canaday5.   

Abstract

BACKGROUND: Seasonal influenza vaccines approved and offered in the United States have varying reported degrees of effectiveness year over year and between manufacturers. Influenza vaccines produced from live virus may include single stranded RNA (ssRNA) that is a potent activator of the innate Toll-like receptor 7 (TLR-7) ligand. Plasmacytoid dendritic cells (pDC) can be activated by ssRNA to produce type I interferons such as IFN-α, which has been shown to have an adjuvant-like effect.
OBJECTIVE: Our aim was to determine if IFN-α induction in peripheral blood mononuclear cells (PBMCs) exposed to eight different commercial influenza vaccines is a pDC-dependent process mediated through TLR-7 signaling.
RESULTS: We demonstrate the ability of multiple vaccines to induce IFN-α in a TLR-7-dependent fashion. A number of vaccines however lacked IFN-α induction. The significance of these differences between vaccines is unclear, since all the approved vaccine formulations offer some degree of protection. Published by Elsevier Ltd.

Entities:  

Keywords:  Human; IFN-α; Immunity; Influenza; Plasmacytoid dendritic cells; Vaccine

Mesh:

Substances:

Year:  2020        PMID: 33390292      PMCID: PMC7855986          DOI: 10.1016/j.vaccine.2020.12.051

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

Review 1.  Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures.

Authors:  Richard E Randall; Stephen Goodbourn
Journal:  J Gen Virol       Date:  2008-01       Impact factor: 3.891

Review 2.  Genetic and mutational analysis of the T-cell antigen receptor.

Authors:  J D Ashwell; R D Klusner
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

3.  Comparative Immunogenicity of Enhanced Seasonal Influenza Vaccines in Older Adults: A Systematic Review and Meta-analysis.

Authors:  Tiffany W Y Ng; Benjamin J Cowling; Hui Zhi Gao; Mark G Thompson
Journal:  J Infect Dis       Date:  2019-04-19       Impact factor: 5.226

Review 4.  The history of MF59(®) adjuvant: a phoenix that arose from the ashes.

Authors:  Derek T O'Hagan; Gary S Ott; Gary Van Nest; Rino Rappuoli; Giuseppe Del Giudice
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

5.  Comparative effectiveness of high dose versus adjuvanted influenza vaccine: A retrospective cohort study.

Authors:  Robertus van Aalst; Stefan Gravenstein; Vincent Mor; Salaheddin M Mahmud; Jan Wilschut; Maarten Postma; Ayman Chit
Journal:  Vaccine       Date:  2019-10-09       Impact factor: 3.641

6.  Efficacy of high-dose versus standard-dose influenza vaccine in older adults.

Authors:  Carlos A DiazGranados; Andrew J Dunning; Murray Kimmel; Daniel Kirby; John Treanor; Avi Collins; Richard Pollak; Janet Christoff; John Earl; Victoria Landolfi; Earl Martin; Sanjay Gurunathan; Richard Nathan; David P Greenberg; Nadia G Tornieporth; Michael D Decker; H Keipp Talbot
Journal:  N Engl J Med       Date:  2014-08-14       Impact factor: 91.245

Review 7.  Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity.

Authors:  Paola Rizza; Franca Moretti; Filippo Belardelli
Journal:  Autoimmunity       Date:  2010-04       Impact factor: 2.815

8.  Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo.

Authors:  M K Jenkins; R H Schwartz
Journal:  J Exp Med       Date:  1987-02-01       Impact factor: 14.307

9.  Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2019-20 Influenza Season.

Authors:  Lisa A Grohskopf; Elif Alyanak; Karen R Broder; Emmanuel B Walter; Alicia M Fry; Daniel B Jernigan
Journal:  MMWR Recomm Rep       Date:  2019-08-23

Review 10.  Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults.

Authors:  Theodore F Tsai
Journal:  Infect Chemother       Date:  2013-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.